Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Belantamab mafodotin-blmf (Blenrep) is used for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
• The document reviewed indicates that belantamab mafodotin-blmf (Blenrep) is part of a new approach using monoclonal antibodies to treat multiple myeloma.
• This drug has been discussed in relation to other similar treatments such as daratumumab and isatuximab which are also directed against CD38, elotuzumab targeting SLAMF7, and nivolumab and pembrolizumab acting on PD-1/PD-L axis.
• According to the literature data until March 22, 2020 analyzed in this review paper, belantamab mafodotin-blmf (Blenrep) shows promising results as salvage therapy in relapsed/refractory myeloma cases where traditional therapies have failed.
• One systematic review/meta-analysis was examined for this summary providing updated information about the use of belantamab mafodotin-blmf (Blenrep).
• Health professionals should consider optimal positioning and selection among different available antibodies like Blenrep while making prescribing decisions; they must also be aware of potential new toxicities associated with these drugs according to expert opinion.